Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.

Sanborn RE, Pishvaian MJ, Callahan MK, Weise A, Sikic BI, Rahma O, Cho DC, Rizvi NA, Sznol M, Lutzky J, Bauman JE, Bitting RL, Starodub A, Jimeno A, Reardon DA, Kaley T, Iwamoto F, Baehring JM, Subramaniam DS, Aragon-Ching JB, Hawthorne TR, Rawls T, Yellin M, Keler T

Open source

DOI: 10.1136/jitc-2022-005147
Published: 2022 Aug
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2022-005147,
  title = {Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.},
  author = {Sanborn RE and Pishvaian MJ and Callahan MK and Weise A and Sikic BI and Rahma O and Cho DC and Rizvi NA and Sznol M and Lutzky J and Bauman JE and Bitting RL and Starodub A and Jimeno A and Reardon DA and Kaley T and Iwamoto F and Baehring JM and Subramaniam DS and Aragon-Ching JB and Hawthorne TR and Rawls T and Yellin M and Keler T},
  year = {2022},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2022-005147},
  url = {https://doi.org/10.1136/jitc-2022-005147}
}

RIS

TY  - JOUR
TI  - Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
AU  - Sanborn RE
AU  - Pishvaian MJ
AU  - Callahan MK
AU  - Weise A
AU  - Sikic BI
AU  - Rahma O
AU  - Cho DC
AU  - Rizvi NA
AU  - Sznol M
AU  - Lutzky J
AU  - Bauman JE
AU  - Bitting RL
AU  - Starodub A
AU  - Jimeno A
AU  - Reardon DA
AU  - Kaley T
AU  - Iwamoto F
AU  - Baehring JM
AU  - Subramaniam DS
AU  - Aragon-Ching JB
AU  - Hawthorne TR
AU  - Rawls T
AU  - Yellin M
AU  - Keler T
PY  - 2022
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2022-005147
UR  - https://doi.org/10.1136/jitc-2022-005147
ER  -

APA

RE, S., MJ, P., MK, C., A, W., BI, S., O, R., DC, C., NA, R., M, S., J, L., JE, B., RL, B., A, S., A, J., DA, R., T, K., F, I., JM, B., DS, S., JB, A., TR, H., T, R., M, Y., & T, K. (2022). Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2022-005147

Source records

pubmed · retrieved 2026-09-27T01:07:40.018Z